Liquid pharmaceutical formulations of anti-GM-CSF antibodies and uses thereof

By using specific antibody sequences and components combinations in liquid drug formulations, the problems of stability and biocompatibility of GM-CSF inhibitors in the treatment of inflammatory and autoimmune diseases have been solved, achieving high concentrations of antibody preparations Stability and efficient delivery.

CN119095584AInactive Publication Date: 2024-12-06I MAB BIOPHARMA (HANGZHOU) CO LTD

Patent Information

Application Number
CN202380030614.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-01
Filing Date
2023-11-30
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing GM-CSF inhibitors have stability and biocompatibility problems in the treatment of inflammatory and autoimmune diseases, making it difficult to effectively prepare high concentrations of antibody preparations, and is difficult to control viscosity and pH, affecting drug delivery and stability.

Method used

A liquid pharmaceutical formulation is provided, comprising 20 mg/ml-200 mg/ml anti-GM-CSF antibody, 10 mM-30 mM buffer, 130 mM-250 mM isoosmotic regulator and 0.01 (w/v)%-0.03 ( w/v)% surfactant, pH range of 4.5-7.5, uses specific antibody sequences and components combinations, including specific amino acid residues in the variable regions of heavy and light chains, for the preparation of stable and efficient Antibody preparation.

Benefits of technology

The stability and biocompatibility of antibody preparations are achieved, high concentration preparation and effective drug delivery are ensured, the instability of viscosity and pH value is reduced, and the therapeutic effect is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005061215800000081
    Figure BDA0005061215800000081
  • Figure BDA0005061215800000091
    Figure BDA0005061215800000091
  • Figure BDA0005061215800000101
    Figure BDA0005061215800000101
Patent Text Reader

Abstract

The present disclosure provides liquid pharmaceutical formulations comprising antibodies that specifically bind to human GM-CSF and additional excipients, as well as methods of using the liquid pharmaceutical formulations to treat inflammatory or autoimmune diseases or conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention claims priority to PCT / CN2022 / 135948 filed on December 1, 2022, the contents of which are incorporated herein in their entirety. Technical Field

[0002] The present disclosure relates to liquid pharmaceutical formulations comprising an anti-GM-CSF antibody. Background Art

[0003] Granulocyte-macrophage colony stimulating factor (GM-CSF), also known as colony stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts that acts as a cytokine. Pharmaceutical analogs of naturally occurring GM-CSF are also known as sargramostim and molgramostim.

[0004] GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils and basophils) and monocytes. Monocytes leave the circulation and migrate into tissues, where they mature into macrophages and dendritic cells. Therefore, it is part of the immune / inflammatory cascade, through which activation of a small number of macrophages can quickly lead to an increase in their number, a key process in combating infection. GM-CSF also has some effects on mature cells of the immune system. These include, for example, inhibiting neutrophil migration and causing changes in receptors expressed on the cell surface.

[0005] GM-CSF signals via signal transducer and transcription activator STAT5. In macrophages, it has also been demonstrated that it signals via STAT3. Cytokines activate macrophages to inhibit fungal survival. It induces deprivation of intracellular free zinc and increases the production of reactive oxygen species, ultimately leading to fungal zinc starvation and toxicity. Therefore, GM-CSF contributes to the development of the immune system and promotes defense against infection. GM-CSF also plays a role in embryonic development by acting as an embryonic factor produced by the reproductive tract.

[0006] Inhibiting GM-CSF can be used to treat diseases such as inflammatory diseases and autoimmune disorders, including rheumatoid arthritis (RA), multiple sclerosis (MS), and plaque psoriasis. Inhibiting GM-CSF can also be used to treat cancer.

[0007] All references cited herein (including patent applications, patent publications, and UniProtKB / Swiss-Prot accession numbers) are incorporated by reference in their entirety to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference. Summary of the invention

[0008] In one aspect of the present disclosure, there is provided a liquid pharmaceutical formulation comprising: a) 20 mg / ml-200 mg / ml of an antibody or an antigen-binding fragment thereof that specifically binds to a human granulocyte macrophage colony-stimulating factor (GM-CSF) protein, wherein the antibody comprises a heavy chain variable region CDR1 (HCDR1) of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, a HCDR3 of SEQ ID NO: 3, a light chain variable region CDR1 (LCDR1) of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6; b) 10 mM-30 mM pH buffer; c) 130 mM to 250 mM isotonicity regulator; and d) 0.01 (w / v)% - 0.03 (w / v)% surfactant, wherein the formulation has a pH of about 4.5 to about 7.5.

[0009] In certain embodiments, the liquid pharmaceutical formulations provided herein comprise an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising one or more amino acid residues selected from the group consisting of: a) Glu at position 1, b) Arg at position 98, c) Ser at position 72, d) Ala at position 68, e) Leu at position 70, f) Ile at position 48, g) Asp at position 26, and h) Leu at position 29, and combinations thereof.

[0010] In certain embodiments, the heavy chain variable region comprises at least (a) Glu at position 1. In certain embodiments, the heavy chain variable region comprises a DYTLT (SEQ ID NO: 23) or GYTFT (SEQ ID NO: 24) fragment starting at position 26 according to Kabat numbering.

[0011] In certain embodiments, the liquid pharmaceutical formulations provided herein comprise an antibody or antigen-binding fragment thereof comprising a light chain variable region comprising one or more amino acid residues selected from the group consisting of: a) Ala at position 46, b) Asp at position 60, c) Asp at position 70, d) Ser at position 43, and e) Phe at position 87, and combinations thereof.

[0012] In certain embodiments, the antibodies or antigen-binding fragments thereof provided herein comprise a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 to 17. In certain embodiments, the liquid pharmaceutical formulations provided herein comprise a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 22.

[0013] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22.

[0014] In certain embodiments, the antibody or antigen-binding fragment thereof further comprises an Fc region. In certain embodiments, the Fc region is an Fc region of IgG1.

[0015] In certain embodiments, the pH buffer comprises citric acid, HEPES, histidine, potassium acetate, potassium citrate, potassium phosphate (KH2PO4), sodium acetate, sodium bicarbonate, sodium citrate, sodium phosphate (NaH2PO4), Tris base, and Tris-HCl.

[0016] In certain embodiments, the pH buffer comprises 20 mM histidine. In certain embodiments, 20 mM histidine comprises about 6.2 mM histidine and about 13.8 mM histidine hydrochloride monohydrate. In certain embodiments, the pH buffer comprises about 20 mM NaAc.

[0017] In certain embodiments, the pH is in the range of about 5.5 to about 6.1. In certain embodiments, the pH is about 5.8.

[0018] In certain embodiments, the isotonicity regulator is one or more selected from the group consisting of: sucrose, trehalose, mannitol, arginine and sodium chloride. In certain embodiments, the isotonicity regulator comprises 200-220mM sucrose. In certain embodiments, the isotonicity regulator comprises about 220mM sucrose.

[0019] In certain embodiments, the liquid pharmaceutical formulation further comprises an antioxidant, a preservative, or a mixture thereof.

[0020] In certain embodiments, the liquid drug formulation further comprises proline and / or glycine.

[0021] In certain embodiments, the surfactant comprises polysorbate 20 or polysorbate 80. In certain embodiments, the surfactant comprises about 0.02 (w / v)% polysorbate 80.

[0022] In certain embodiments, the liquid pharmaceutical formulation comprises 50 mg / ml-150 mg / ml of the antibody. In certain embodiments, the liquid pharmaceutical formulation comprises about 100 mg / ml of the antibody.

[0023] In certain embodiments, the liquid drug formulation comprises 50-150 mg / ml of the antibody, 10-20 mM histidine, 200-220 mM sucrose, and 0.01-0.03 (w / v)% polysorbate 80, and has a pH of about 5.5 to about 6.1.

[0024] In certain embodiments, the liquid drug formulation comprises about 100 mg / ml of the antibody, about 20 mM histidine, about 220 mM sucrose, and about 0.02 (w / v)% polysorbate 80, and has a pH of about 5.8.

[0025] In certain embodiments, liquid drug formulations are for intravenous (IV) or subcutaneous administration.

[0026] In another aspect of the present disclosure, provided is a method of treating an inflammatory or autoimmune disease or condition in a patient in need thereof, the method comprising administering to the patient a liquid pharmaceutical formulation provided herein.

[0027] In certain embodiments, the autoimmune disease is selected from the group consisting of alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, diabetes mellitus (type 1), celiac disease, autoimmune juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, autoimmune myocarditis, multiple sclerosis, pemphigus / pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, scleroderma / systemic sclerosis, Sjögren's syndrome ( syndrome), systemic lupus erythematosus, autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune uveitis, vitiligo, and granulomatosis with polyangiitis (Wegener's granulomatosis).

[0028] In certain embodiments, the inflammatory disease is selected from the group consisting of: Alzheimer's disease, Addison's disease, atherosclerosis, ankylosing spondylitis, arthritis, osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PA), ankylosing spondylitis, asthma, atherosclerosis, chronic obstructive pulmonary disease (COPD), Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematosus (SLE), nephritis, Parkinson's disease (PD), vasculitis, ulcerative colitis and COVID-19. DETAILED DESCRIPTION

[0029] Before describing the present disclosure in detail, it should be understood that the present disclosure is not limited to the specific compositions or biological systems described, which may of course vary. It should also be understood that the terms used herein are for the purpose of illustrating specific embodiments only and are not intended to be limiting. As used in this specification and the appended claims, the singular forms "a / an" and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, a reference to a "molecule" optionally includes a combination of two or more such molecules, etc.

[0030] As used herein, the term "about" refers to the usual error range of the corresponding value that is readily known to those skilled in the art. References herein to "about" values ​​or parameters include (and describe) embodiments involving the value or parameter itself. In the event of doubt or there is no common understanding in the art regarding the error range of a value or parameter, "about" means ± 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% of the value or parameter.

[0031] It should be understood that the aspects and embodiments of the present disclosure described herein include "comprising the aspects and embodiments," "consisting of the aspects and embodiments," and "consisting essentially of the aspects and embodiments."

[0032] The term "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredient to be effective, and that contains no other components that are unacceptably toxic to a subject to which the formulation is administered. Such formulations are sterile. Anti-GM-CSF antibody

[0033] The pharmaceutical formulation of the present disclosure may include an antibody or antigen-binding fragment thereof that specifically binds to human GM-CSF. As used herein, the term "GM-CSF" means human granulocyte macrophage colony stimulating factor. Antibodies against human GM-CSF are described, for example, in WO 2006122797, WO 2015028657, and WO 2018050111.

[0034] As used herein, the term "antibody" is generally intended to refer to immunoglobulin molecules comprising four polypeptide chains (two heavy (H) chains and two light (L) chains interconnected by disulfide bonds) and multimers thereof (e.g., IgM); however, immunoglobulin molecules consisting only of heavy chains (i.e., lacking light chains) are also encompassed within the definition of the term "antibody". Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region comprises three domains, CH1, CH2, and CH3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region comprises one domain (CL1). The VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from amino-terminus to carboxyl-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0035] Unless otherwise specifically stated, as used herein, the term "antibody" should be understood to cover intact antibody molecules and antigen-binding fragments thereof. As used herein, the term "antigen-binding portion" or "antigen-binding fragment" of an antibody (or simply "antibody portion" or "antibody fragment") refers to one or more fragments of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc., which retain the ability to specifically bind to human GM-CSF or its epitope.

[0036] As used herein, "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (eg, an isolated antibody that specifically binds human GM-CSF is substantially free of antibodies that specifically bind antigens other than human GM-CSF).

[0037] The term "specific binding" and the like means that the antibody or its antigen-binding fragment forms a relatively stable complex with the antigen under physiological conditions. Specific binding can be achieved by at least about 1×10 -8 The method for determining whether two molecules specifically bind is known in the art and includes, for example, equilibrium dialysis, surface plasmon resonance, and the like. However, an isolated antibody that specifically binds to human GM-CSF may have cross-reactivity with other antigens, such as GM-CSF from other species (orthologs). In the context of the present disclosure, a multispecific (e.g., bispecific) antibody that binds to human GM-CSF and one or more additional antigens is considered to "specifically bind" to human GM-CSF. Moreover, the isolated antibody may be substantially free of other cellular material or chemicals.

[0038] Exemplary anti-human GM-CSF antibodies that may be included in the pharmaceutical formulations of the present disclosure are described in patent application WO2018050111, the disclosure of which is incorporated by reference in its entirety.

[0039] According to certain embodiments of the present disclosure, the anti-human GM-CSF antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO: 3. In certain embodiments, the anti-human GM-CSF antibody or antigen-binding fragment thereof comprises a HCVR of SEQ ID NO: 14.

[0040] According to certain embodiments of the present disclosure, the anti-human GM-CSF antibody or antigen-binding fragment thereof comprises a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 4, a LCDR2 of SEQ ID NO: 5, and a LCDR3 of SEQ ID NO: 6. In certain embodiments, the anti-human GM-CSF antibody or antigen-binding fragment thereof comprises a LCVR of SEQ ID NO: 22.

[0041] According to one embodiment of the present disclosure, an antibody is provided, comprising heavy and light chain variable domains having CDR regions as defined in SEQ ID NOs: 1-6, as shown below. Table 1. Sequences of the CDR regions of 23F4 name sequence SEQ ID NO: VH CDR1 SHYL 1 VH CDR2 WIFPGDDKTKYNEKFKG 2 VH CDR3 GTKYLNWNFDV 3 VL CDR1 KANQNVGTTLA 4 VL CDR2 SASYRYS 5 VL CDR3 HQYTTYPLT 6

[0042] In some embodiments, the anti-GM-CSF antibodies of the disclosure comprise the VH and VL CDRs listed in Table 1, with one, two or three further modifications. Such modifications may be additions, deletions or substitutions of amino acids.

[0043] In some embodiments, the modification is a substitution at no more than one residue from each CDR. In some embodiments, the modification is a substitution at one, two, or three residues. In one embodiment, the modification is a substitution at one of the residues. In some embodiments, such substitutions are conservative substitutions.

[0044] "Conservative amino acid substitutions" are substitutions in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including: basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, it is preferred that a non-essential amino acid residue in an immunoglobulin polypeptide is replaced with another amino acid residue from the same side chain family. In another embodiment, a string of amino acids can be replaced with a string of structurally similar amino acids that differ in order and / or composition of side chain family members.

[0045] In some embodiments, the antibody or fragment thereof comprises at most one, at most two, or at most three of the above substitutions.

[0046] In some embodiments, the antibody or fragment thereof is specific for human GM-CSF protein and comprises HCDR1 of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, LCDR1 of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6. Non-limiting examples of VH are provided in SEQ ID NO: 7-17, wherein SEQ ID NO: 7 is a mouse VH, and SEQ ID NO: 8-17 are humanized VH. In addition, these humanized VHs include one or more back mutations of the mouse variant. Similarly, non-limiting examples of VL (Vκ) are provided in SEQ ID NO: 18-22. SEQ ID NO: 18 is a mouse sequence, and SEQ ID NO: 19-22 are humanized sequences, wherein SEQ ID NO: 20-22 include one or more back mutations, as shown in the Examples. The amino acid and nucleotide sequences of some humanized antibodies 23F4 are listed in Table 2 below. The combinations of heavy chain variable regions and light chain variable regions are shown in Table 3. Table 2. Humanized antibody sequences (CDR residues are underlined and back mutations are in indicated boxes) Table 3. VH / Vκ combinations used for humanized antibody 23F4

[0047] Back mutations have been shown to be useful for retaining certain features of anti-GM-CSF antibodies. Thus, in some embodiments, the anti-GM-CSF antibodies (particularly human or humanized antibodies) disclosed herein comprise one or more back mutations. In some embodiments, the VH back mutation (i.e., including the amino acid at the specified position) is selected from one or more of the following according to Kabat numbering: (a) Glu at position 1 (E1), (b) Arg at position 98 (R98), (c) Ser at position 72 (S72), (d) Ala at position 68 (A68), (e) Leu at position 70 (L70), (f) Ile at position 48 (I48), (g) Asp at position 26 (D26) and (h) Leu at position 29 (L29), and combinations thereof.

[0048] In some embodiments, the humanized antibody comprises at least VH reversion mutation E1. In some embodiments, the humanized antibody comprises at least VH reversion mutation E1 and R98. In some embodiments, the humanized antibody comprises at least VH reversion mutation E1 and another as listed above. In some embodiments, the humanized antibody comprises at least VH reversion mutation group (E1, R98 and S72), (E1, R98, S72 and A68), (E1, R98, S72, A68, L70 and I48), (E1, R98, S72, A68, L70, I48, D26 and L29), (E1 and S72), (E1, S72 and L70), (E1, S72, L70, I48 and A68), (E1, S72, L70, I48, A68, D26 and L29).

[0049] In some embodiments, the heavy chain variable region comprises a DYTLT (SEQ ID NO: 23) or GYTFT (SEQ ID NO: 24) segment at the N-terminus of CDR1, i.e., starting at position 26 according to Kabat numbering. In one embodiment, the heavy chain variable region comprises DYTLT (SEQ ID NO: 23). In one embodiment, the heavy chain variable region comprises GYTFT (SEQ ID NO: 24).

[0050] In some embodiments, the humanized antibody comprises one or more of the back mutations. In some embodiments, the VL back mutation is selected from one or more of the following according to Kabat numbering: (a) Ala at position 46 (A46), (b) Asp at position 60 (D60), (c) Asp at position 70 (D70), (d) Ser at position 43 (S43) and (f) Phe at position 87 (F87), and combinations thereof.

[0051] In some embodiments, the humanized antibody comprises at least two, three or four of the VL reversion mutations A46, D60, D70, S43 or F87. In some embodiments, the humanized antibody comprises at least the VL reversion mutation A46. In some embodiments, the humanized antibody comprises at least the VL reversion mutations A46 and D60 and another one listed above. In some embodiments, the humanized antibody comprises at least the VL reversion mutation group (A46, D60 and D70) or (A46, D60, D70, S43 and F87).

[0052] In some embodiments, the humanized antibody comprises at least VH back mutations (E1, R98, S72, A68, L70 and I48) and no VL back mutations. In some embodiments, the humanized antibody comprises at least VH back mutations (E1, S72, L70, I48, A68, D26 and L29) and no VL back mutations. In some embodiments, the humanized antibody comprises at least VH back mutations (E1 and S72) and VL back mutations (A46, D60, D70, S43 and F87).

[0053] In some embodiments, the anti-GM-CSF antibodies of the present disclosure comprise the VH of SEQ ID NOs: 8-17 and the VL of SEQ ID NOs: 19-22, or their respective biological equivalents. A biological equivalent of a VH or VL is a sequence comprising the specified amino acids while having an overall 80%, 85%, 90%, 95%, 98% or 99% sequence identity. Thus, a biological equivalent of SEQ ID NO: 10 may be a VH having an overall 80%, 85%, 90%, 95%, 98% or 99% sequence identity to SEQ ID NO: 10 but retaining the CDRs (SEQ ID NOs: 1-3 or variants thereof), and optionally retaining one or more or all back mutations.

[0054] In one embodiment, VH has an amino acid sequence of SEQ ID NO: 11, and VL has an amino acid sequence of SEQ ID NO: 19. In one embodiment, VH has an amino acid sequence of SEQ ID NO: 17, and VL has an amino acid sequence of SEQ ID NO: 19. In one embodiment, VH has an amino acid sequence of SEQ ID NO: 11, and VL has an amino acid sequence of SEQ ID NO: 22. It is worth noting that each of the listed sequences can also be substituted with their biological equivalents.

[0055] It will also be appreciated by those of ordinary skill in the art that the antibodies disclosed herein may be modified so that they differ in amino acid sequence from the naturally occurring binding polypeptides from which they are derived. For example, a polypeptide or amino acid sequence derived from a given protein may be similar to the starting sequence, e.g., have a certain percentage of identity, e.g., it may have 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to the starting sequence.

[0056] In certain embodiments, the antibodies provided herein further comprise a heavy chain constant region, a light chain constant region, an Fc region, or a combination thereof.

[0057] The Fc region can be engineered to enhance or eliminate effector functions. IgG antibodies can induce direct anti-tumor effects in an indirect anti-tumor effect manner through Fc-mediated effector functions that engage other immune cells or killing mechanisms. As used herein, "effector function" or "antibody effector function" refers to the biological activity attributable to the binding of the Fc region of an antibody to its effector, such as the C1 complex and the Fc receptor (FcγRIIa or FcγRIIIa). Exemplary effector functions include complement-dependent cytotoxicity (CDC) induced by the interaction of the antibody and C1q on the C1 complex; antibody-dependent cell-mediated cytotoxicity (ADCC) induced by binding of the Fc region of the antibody to the Fc receptor on the effector cell; and antibody-dependent cell-mediated phagocytosis (ADCP), in which nonspecific cytotoxic cells expressing Fcγ receptors (FcγRs) recognize the bound antibody on the target cell and subsequently cause phagocytosis of the target cell.

[0058] Among the four IgG subclasses, IgG1 and IgG3 induce the strongest Fc effector functions. However, since IgG1 has the longest half-life and is more stable than IgG3, most therapeutic antibodies with Fc-mediated functions are of the IgG1 isotype.

[0059] IgG2 and IgG4 isotypes have significantly lower binding affinities for FcγRs. Recent evidence suggests that the IgG2 isotype is not completely devoid of effector function, whereas the IgG4 isotype can undergo Fab arm exchange in vivo, resulting in bispecific antibodies and off-target effects.

[0060] In certain embodiments, the isotype of the antibodies provided herein is IgGl. In certain embodiments, the isotype of the antibodies is human IgGl.

[0061] In some embodiments, the antibodies and fragments disclosed herein may be monospecific or bispecific antibodies or fragments. For bispecific antibodies, additional specificities may be different target epitopes for GM-CSF or different target proteins that may be used for a specific purpose (e.g., therapeutic use). In one aspect, the target protein is a cytokine such as TNF-α, IL-6, IL-1, and IL-17. In another aspect, the target protein is a chemokine such as CCL2, CXCL12, and CXCL13. In another aspect, the target protein is a cell surface protein such as CD3, CSF-1R, CD20, and CD73.

[0062] In certain embodiments, the antibody comprises an amino acid sequence or one or more moieties that are not normally associated with the antibody. Exemplary modifications are described in more detail below. For example, the antibody of the present disclosure may comprise a flexible linker sequence, or may be modified to add a functional moiety (e.g., PEG, a drug, a toxin, or a marker).

[0063] The antibodies, variants or derivatives thereof disclosed herein include modified derivatives, i.e., by covalently attaching any type of molecule to the antibody so that the covalent attachment does not hinder the antibody from binding to the epitope. For example, but not limited to, the antibody can be modified, for example, by glycosylation, acetylation, pegylation, phosphorylation, phosphorylation, amidation, derivatization with known protecting groups / blocking groups, proteolytic cleavage, connection to cellular ligands or other proteins. Any of a number of chemical modifications can be performed by known techniques, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. In addition, the antibody can contain one or more non-classical amino acids.

[0064] In some embodiments, the antibody can be conjugated or connected to another molecule to form a bifunctional molecule by other means. The second molecule can be one of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a medicament or PEG. Some non-limiting examples are cytokines or other soluble factors, such as IL-10, IL-25, IL-27, IL-33, IL-35 and IL-36. In some embodiments, an antibody-drug conjugate is also provided, which includes an antibody or fragment of the present disclosure and a small molecule drug.

[0065] The antibody may be conjugated or fused to a therapeutic agent, which may include a detectable label (such as a radioactive label), an immunomodulatory agent, a hormone, an enzyme, an oligonucleotide, a photoactive therapeutic or diagnostic agent, a cytotoxic agent (which may be a drug or a toxin), an ultrasound enhancing agent, a non-radioactive label, combinations thereof, and other such agents known in the art. Pharmaceutical preparations

[0066] The formulated antibodies are preferably substantially pure, and desirably substantially homogeneous (e.g., free of contaminating proteins, etc.). By "substantially pure" antibody is meant a composition comprising at least about 90% by weight of the antibody, preferably a composition comprising at least about 95% by weight of the antibody, based on the total weight of protein in the composition, and by "substantially homogeneous" antibody is meant a composition comprising at least about 99% by weight of the antibody, based on the total weight of protein in the composition.

[0067] The term "pharmaceutical formulation" refers to a preparation containing an anti-GM-CSF antibody in a form that permits the biological activity of the active ingredient to be effective, and that contains no additional components that are unacceptably toxic to a subject to which the formulation would be administered.

[0068] The formulation may be liquid.Liquid formulations are aqueous solutions or suspensions prepared in a suitable aqueous solvent such as water or an aqueous / organic mixture such as a hydroalcoholic mixture.

[0069] In certain embodiments, the liquid drug formulation comprises 20 mg / ml-200 mg / ml (e.g., 30 mg / ml-200 mg / ml, 40 mg / ml-200 mg / ml, 50 mg / ml-200 mg / ml, 60 mg / ml-200 mg / ml, 70 mg / ml-200 mg / ml, 80 mg / ml-200 mg / ml, 90 mg / ml-200 mg / ml, 100 mg / ml-200 mg / ml, 110 mg / ml-200 mg / ml, mg / ml, 120mg / ml-200mg / ml, 130mg / ml-200mg / ml, 140mg / ml-200mg / ml, 150mg / ml-200mg / ml, 160mg / ml-200mg / ml, 170mg / ml-200mg / ml, 180mg / ml-200mg / ml, 190mg / ml-200mg / ml, 20mg / ml-190mg / ml, 20mg / ml-180mg / ml, 2 0mg / ml-170mg / ml, 20mg / ml-160mg / ml, 20mg / ml-150mg / ml, 20mg / ml-140mg / ml, 20mg / ml-130mg / ml, 20mg / ml- 120mg / ml, 20mg / ml-110mg / ml, 20mg / ml-100mg / ml, 20mg / ml-90mg / ml, 20mg / ml-80mg / ml, 20mg / ml-70mg / ml, 20 mg / ml-60mg / ml, 20mg / ml-50mg / ml, 20mg / ml-40mg / ml, 30mg / ml-190mg / ml, 40mg / ml-180mg / ml, 50mg / ml-170mg / ml, 60mg / ml-160mg / ml, 70mg / ml-150mg / ml, 80mg / ml-140mg / ml, 90mg / ml-130mg / ml, 100mg / ml-120mg / ml) antibodies. In certain embodiments, the liquid drug formulation comprises 20 mg / ml, 30 mg / ml, 40 mg / ml, 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, 100 mg / ml, 110 mg / ml, 120 mg / ml, 130 mg / ml, 140 mg / ml, 150 mg / ml, 160 mg / ml, 170 mg / ml, 180 mg / ml, 190 mg / ml, or 200 mg / ml of antibody.

[0070] In another embodiment, the pharmaceutical formulation further comprises an additional excipient. The term "excipient" as used herein refers to an inert substance commonly used as a diluent, vehicle, preservative, binder or stabilizer for a drug that imparts beneficial physical properties to the formulation, such as increasing protein stability, increasing protein solubility and reducing viscosity.

[0071] "Excipients" include, but are not limited to: stabilizers, such as human serum albumin (HSA), bovine serum albumin (BSA), α-casein, globulin, α-lactalbumin, LDH, lysozyme, myoglobin, ovalbumin, RNase A; buffers, such as citric acid, HEPES, PBS, histidine, potassium acetate, potassium citrate, potassium phosphate (KH2PO4), sodium acetate, sodium bicarbonate, sodium citrate, sodium phosphate (NaH2PO4), Tris base and Tris-HCl; amino acids / metabolites, such as glycine, alanine (α-alanine, β-alanine), arginine, betaine, leucine, lysine, glutamic acid, aspartic acid, histidine, proline, 4-hydroxyproline, sarcosine, γ-aminobutyric acid (GABA), opines (alanopine, octopine, strombine) and trimethylamine N-oxide (TMAO); surfactants, such as polysorbate 60, ester 20 and polysorbate 80 and poloxamer 407; lipid molecules such as phosphatidylcholine, ethanolamine and acetyltryptophan ester; polymers such as polyethylene glycol (PEG) and polyvinylpyrrolidone (PVP) 10, 24, 40; low molecular weight excipients such as arabinose, cellobiose, ethylene glycol, fructose, fucose, galactose, glycerol / glycerol, glucose, inositol, lactose, maltose, maltotriose, mannose, melibiose, 2-methyl-2,4-pentanediol , octulose, propylene glycol, raffinose, ribose, sucrose, trehalose, xylitol and xylose; and high molecular weight excipients such as cellulose, β-cyclodextrin, dextran (10 kd), dextran (40 kd), dextran (70 kd), polysucrose, gelatin, hydroxypropyl methylcellulose, hydroxyethyl starch, maltodextrin, methylcellulose, PEG (6 kd), polydextrose, polyvinylpyrrolidone (PVP) k15 (10 kd), PVP (40 kd), PVP k30 (40 kd), PVP k90 (1000 kd), dextran gel G-200 and starch; antioxidants such as ascorbic acid, cysteine ​​hydrochloride, monothioglycerol, thioglycolic acid, thiosorbitol and glutathione; reducing agents such as cysteine ​​hydrochloride, dithiothreitol and other thiols or thiophenes; chelating agents such as EDTA, EGTA, glutamic acid and aspartic acid; inorganic salts / metals such as Ca 2 +、Ni 2 +、Mg 2 +、Mn 2+, Na2SO4, (NH4)2SO4, Na2HPO4 / NaH2PO4, K2HPO4 / KH2PO4, MgSO4 and NaF; organic salts such as sodium acetate, sodium polyvinyl, sodium caprylate / Na octanoate, proprionate, lactate, succinate and citrate; organic solvents such as acetonitrile, dimethyl sulfoxide (DMSO) and ethanol. For additional information on excipients, see Remington's Pharmaceutical Sciences (Joseph P. Remington, 18th ed., Mack Publishing Co., Easton, Pa.), which is incorporated herein in its entirety.

[0072] "Iso-osmotic" means that the target preparation has the osmotic pressure substantially the same as human blood. Isotonic preparations generally have an osmotic pressure of about 250 to about 350mOsm (e.g., about 250 to about 340, about 250 to about 330, about 250 to about 320, about 250 to about 310, about 250 to about 300, about 260 to about 350, about 270 to about 350, about 280 to about 350, about 290 to about 350, about 300 to about 350, about 260 to about 340, about 270 to about 330, about 280 to about 320, about 290 to about 310mOsm). Isotonic pressure can be measured using, for example, vapor pressure or a freezing type osmometer. In certain embodiments, isotonic pressure is about 300mOsm. In certain embodiments, isotonic pressure regulators can be one or more selected from the group consisting of: sucrose, trehalose, mannitol, arginine and sodium chloride. In certain embodiments, the range of the isotonicity adjusting agent is about 130-250mM (e.g., about 130mM to about 240mM, about 150mM to about 240mM, about 180mM to about 240mM, about 200mM to about 240mM, about 130mM to about 220mM, about 150mM to about 220mM, about 180mM to about 220mM, about 130mM to about 210mM, about 150mM to about 210mM, about 180mM to about 210mM, about 200mM to about 220mM, or about 200 to about 210mM). In some embodiments, the isotonicity adjusting agent is about 130mM, about 140mM, about 150mM, about 160mM, about 170mM, about 180mM, about 190mM, about 200mM, about 210mM, about 220mM, about 230mM, about 240mM or about 250mM. In certain embodiments, the isotonicity adjusting agent comprises sucrose or trehalose.

[0073] As used herein, "pH buffer" refers to a buffered solution that resists pH changes through the action of its acid-base conjugate components. Preferably, the buffer of the present disclosure has a pH in the range of about 4.5 to about 7.5 (preferably about 5.0 to about 7.0, such as about 5.0 to about 6.9, about 5.2 to about 6.8, about 5.3 to about 6.7, about 5.4 to about 6.6, about 5.5 to about 6.5, about 5.6 to about 6.4, about 5.7 to about 6.3, about 5.8 to about 6.2, about 5.9 to about 6.1, about 5.5 to about 6.4, about 5.5 to about 6.3, about 5.5 to about 6.2, about 5.5 to about 6.1 or about 5.5 to about 6.0). In some embodiments, the buffer has a pH of about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, or 7.0. In one embodiment, the buffer has a pH of 5.8. The desired pH level can be achieved by a variety of methods, including but not limited to the addition of a suitable buffer.

[0074] In certain embodiments, the pH buffer comprises histidine, acetate, citrate, and succinate. In certain embodiments, the pH buffer comprises about 10 to about 30 mM histidine and / or about 10 to about 30 mM acetate, such as about 10 to about 25 mM, about 10 to about 20 mM, or about 15 mM to about 20 mM histidine and / or about 10 to about 25 mM, about 10 mM to about 20 mM, or about 15 mM to about 20 mM acetate. In some embodiments, the pH buffer comprises about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, about 30 mM histidine or acetate.

[0075] In certain embodiments, the pH buffer comprises L-histidine and histidine hydrochloride monohydrate. In certain embodiments, the pH buffer comprises 20 mM histidine, the histidine comprises about 4.4 mM L-histidine and about 15.6 mM histidine hydrochloride monohydrate, about 5.2 mM L-histidine and about 14.8 mM histidine hydrochloride monohydrate, about 6.2 mM L-histidine and about 13.8 mM histidine hydrochloride monohydrate, about 6.8 mM L-histidine and about 13.2 mM histidine hydrochloride monohydrate, about 7.8 mM L-histidine and about 12.2 mM histidine hydrochloride monohydrate, about 8.4 mM L-histidine hydrochloride monohydrate and about 11.6 mM histidine hydrochloride monohydrate, or about 9 mM L-histidine and about 11 mM histidine hydrochloride monohydrate.

[0076] As used herein, "surfactant" refers to an agent having surface activity, preferably a nonionic surfactant. Examples of surfactants herein include polysorbates (e.g., polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, and polysorbate 85); Poloxamers (e.g., poloxamer 188 and poloxamer 407); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate; sodium octyl glucoside (sodium octyl sulfate); glycoside); lauryl-sultaine, myristyl-sultaine, linoleyl-sultaine or stearyl-sultaine; lauryl-sarcosine, myristyl-sarcosine, linoleyl-sarcosine or stearyl-sarcosine; linoleyl-betaine, myristyl-betaine or cetyl-betaine; lauramidopropyl-betaine, cocamidopropyl-betaine, linoleamidopropyl-betaine, myristamidopropyl-betaine, palmitamidopropyl-betaine or isostearamidopropyl-betaine (e.g., lauramidopropyl); myristamidopropyl-dimethylamine, palmitamidopropyl-dimethylamine or isostearamidopropyl-dimethylamine; sodium methyl cocoyl taurate or disodium methyl oleyl taurate; and MONAQUAT TM series (Mona Industries, Inc., Paterson, NJ); polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Piuronics, PF68, etc.); and the like.

[0077] The surfactant concentration is typically about 0.0001% to about 1.0%, about 0.01% to about 0.5%, such as about 0.015 (w / v)% to about 0.03 (w / v)%, about 0.02 (w / v)% to about 0.03 (w / v)%, about 0.025 (w / v)% to about 0.03 (w / v)%, about 0.01 (w / v)% to about 0.025 (w / v)%, about 0.01 (w / v)% to about 0.02 (w / v)% or about 0.01 (w / v)% to about 0.015 (w / v)%. In one embodiment, the surfactant provided herein comprises polysorbate 80 or polysorbate 20. In certain embodiments, the surfactant comprises about 0.01 (w / v)%, 0.015 (w / v)%, 0.02 (w / v)%, 0.025 (w / v)%, or 0.03 (w / v)% polysorbate 80 or polysorbate 20. In certain embodiments, the surfactant comprises about 0.02 (w / v)% polysorbate 80.

[0078] In certain embodiments, the liquid pharmaceutical formulation further comprises an antioxidant, a preservative, or a mixture thereof.

[0079] The term "antioxidant" refers to an agent that inhibits oxidation of other molecules. Examples of antioxidants include ascorbic acid, citrate, lipoic acid, uric acid, cysteine ​​hydrochloride, monothioglycerol, thioglycerol, thioglycolic acid, thiosorbitol, tocopherol, carotene, lycopene, and glutathione; reducing agents such as cysteine ​​hydrochloride, dithiothreitol, phosphonate compounds such as etidronic acid, deferoxamine, and malate, and other thiols or thiophenes and methionine. In other embodiments, the antioxidant is a metal chelator. Metal chelators include, but are not limited to, ethylenediaminetetraacetate ("EDTA"), ethylene glycol tetraacetic acid ("EGTA"), tetrahydrofuranmethyldithiothiamine ("TTFD"), and 2,3-dimercaptosuccinic acid ("DMSA"). In certain embodiments, the formulation comprises about 1 mM to about 50 mM antioxidant. In one embodiment, the formulation comprises about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, or about 45 mM antioxidant.

[0080] The term "preservative" refers to a pharmaceutically acceptable excipient that prevents the growth of microorganisms within the composition. More particularly, the present disclosure provides a multi-dose liquid composition containing a preservative that protects the composition from microbial contamination.

[0081] In one embodiment, the preservative is present in the composition in an amount of 0.001 to 2% (w / v). In one embodiment, the preservative is present in the composition in an amount of 0.002 to 1% (w / v). In one embodiment, the one or more preservatives are selected from phenol, meta-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, para-chloro-meta-cresol, methylparaben, propylparaben, benzalkonium chloride, thimerosal or any combination thereof. In one embodiment, the one or more preservatives are selected from phenol, meta-cresol, benzyl alcohol and chlorobutanol.

[0082] The viscosity of the anti-GM-CSF antibody formulation can be controlled for subcutaneous, intravenous, or intramuscular administration. Viscosity can be affected by protein concentration and pH. For example, as protein concentration increases, viscosity can increase. Increasing pH can reduce the viscosity of the anti-GM-CSF antibody formulation. In some protein formulations, sodium chloride is added to reduce the viscosity of the formulation. Other components that can affect the viscosity of the anti-GM-CSF antibody formulation are amino acids, such as histidine and arginine.

[0083] The liquid drug formulations described herein can have a variety of viscosities. Methods for measuring the viscosity of liquid drug formulations are known to those skilled in the art, and may include, for example, a rheometer (e.g., Anton Paar MCR301 Rheometer with 50mm, 40mm or 20mm cone accessories). In some embodiments of the present disclosure, viscosity is reported at a high shear limit of 1000 / second shear rate. In some embodiments, the liquid drug formulation has a viscosity between 1.0cP ± 10% and 20cP ± 10%. In some embodiments, the liquid drug formulation has a viscosity of less than 20cP, less than 18cP, less than 15cP, less than 13cP or less than 11cP. It will be appreciated by those skilled in the art that viscosity depends on temperature, and therefore, unless otherwise stated, the viscosity provided herein is measured at 25°C, unless otherwise stated. In some embodiments, the viscosity of the liquid drug formulation at 25° C. is 1.0 cP ± 10%, 2.0 cP ± 10%, 3.0 cP ± 10%, 3.1 cP ± 10%, 3.2 cP ± 10%, 3.5 cP ± 10%, 3.6 cP ± 10%, 3.8 cP ± 10%, 4.0 cP ± 10%, 5.0 cP ± 10%, 5.3 cP ± 10%, 6.0 cP ± 10%, 6.3 cP ± 10%, ±10%, 6.4cP±10%, 6.8cP±10%, 7.0cP±10%, 7.1cP±10%, 7.4cP±10%, 8.0cP±10%, 9.0cP±10%, 10.0cP±10%, 11.0cP±10%, 12.0cP±10%, 13.0cP±10%, 14.0cP±10%, 15.0cP±10% or 16cP±10%.

[0084] In certain embodiments, the liquid drug formulation further comprises a viscosity modifier. In one embodiment, the viscosity modifier is an amino acid. In one embodiment, the viscosity modifier is L-proline. In certain embodiments, the concentration of the viscosity modifier is 1% ± 0.2% to 5% ± 1% w / v. In one embodiment, the viscosity modifier is proline at a concentration of 1.5% ± 0.3% or about 1.5%. In one embodiment, the viscosity modifier is proline at a concentration of 3% ± 0.6% or about 3%.

[0085] In a first aspect, the present disclosure provides a novel liquid pharmaceutical formulation comprising: a) an anti-GM-CSF antibody at a concentration of 20 mg / ml-200 mg / ml as an antibody; b) acetate or histidine at a concentration of 10 mM to 30 mM as a buffer; c) sucrose or trehalose at a concentration of 130 mM to 250 mM as an isotonicity regulator; d) polysorbate 80 or polysorbate 20 at a concentration of 0.01 (w / v) % to 0.03 (w / v) % as a surfactant; The pH of the formulation is from about 4.5 to about 7.5, preferably from about 5.5 to about 6.1.

[0086] In a further embodiment, the formulation comprises no other excipients.

[0087] In a preferred embodiment, the present disclosure provides a novel liquid pharmaceutical formulation comprising: a) anti-GM-CSF antibody at a concentration of 50 mg / ml-150 mg / ml; b) histidine at a concentration of 10 mM to 20 mM; c) sucrose at a concentration of 200 mM-220 mM; d) polysorbate 80 at a concentration of 0.01 (w / v)% to 0.03 (w / v)%; Wherein the formulation has a pH of 5.5 to 6.1.

[0088] In a further embodiment, the formulation comprises no other excipients.

[0089] In a more preferred embodiment, the present disclosure provides a novel liquid pharmaceutical formulation comprising: a) an anti-GM-CSF antibody at a concentration of 100 mg / ml, wherein the anti-GM-CSF antibody comprises a heavy chain variable region CDR1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, a light chain variable region CDR1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6; b) histidine at a concentration of 20 mM; c) sucrose at a concentration of 220 mM; d) polysorbate 80 at a concentration of 0.02 (w / v)%; The formulation had a pH of 5.8.

[0090] In a further embodiment, the formulation comprises no other excipients.

[0091] The pharmaceutical formulation can be administered to the patient by a parenteral route such as injection (e.g., subcutaneous, intravenous, intramuscular, intraperitoneal, etc.) or transdermal, mucosal, nasal, pulmonary or oral administration. Many reusable pen or automatic syringe delivery devices can be used for subcutaneous delivery of the pharmaceutical formulation of the present disclosure. Examples include, but are not limited to: AUTOPENTM (Owen Mumford, Inc., Woodstock, UK), DISETRONIC TM Pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75 / 25 TM Pen, HUMALOG TM Pen, HUMALIN 70 / 30 TM PEN (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN TM I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR TM (Novo Nordisk, Copenhagen, Denmark), BD TM PEN (BD Company (BectonDickinson), Franklin Lakes, New Jersey), OPTIPEN TM 、OPTIPEN PRO TM , OPTIPEN STARLET TM and OPTICLIK TM (sanofi-aventis, Frankfurt, Germany). Examples of disposable pen or auto-injector delivery devices for subcutaneous delivery of the pharmaceutical compositions of the present disclosure include, but are not limited to: SOLOSTAR TM Pen (Sanofi-Aventis), FLEXPEN TM (Novo Nordisk) and KWIKPEN TM (Eli Lilly), SURECLICK TM Autoinjector (Amgen, Thousand Oaks, Calif.), PENLET TM (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP), and HUMIRA TM Pen (Abbott Labs, Abbott Park, Ill.).

[0092] It is also contemplated herein to use a microinfusion device to deliver the pharmaceutical formulations disclosed herein. As used herein, the term "microinfusion device" means a subcutaneous delivery device designed to slowly administer a large volume (e.g., up to about 2.5 mL or more) of a therapeutic formulation over an extended period of time (e.g., about 10, 15, 20, 25, 30 or more minutes). See, e.g., U.S. Patent No. 6,629,949; U.S. Patent No. 6,659,982; and Meehan et al., J. Controlled Release [Journal of Controlled Release] 46: 107-116 (1996). Microinfusion devices are particularly suitable for delivering large doses of therapeutic proteins contained in high concentrations (e.g., about 100, 125, 150, 175, 200 mg / mL or higher) or viscous solutions.

[0093] In certain embodiments, the present disclosure provides a prefilled syringe comprising any one of the liquid formulations described herein. In certain embodiments, the syringe is a 1 mL or 2.25 mL long glass syringe filled with a 27-gauge thin-walled needle, a fluorocarbon-coated rubber plunger, and a rubber needle shield.

[0094] In one aspect, the liquid pharmaceutical formulations of the disclosure can be stored at room temperature, refrigerated (eg, 2-8°C), or frozen (eg, -20°C or -70°C).

[0095] In certain embodiments, the formulation of any of the foregoing aspects has a property selected from the group consisting of: (i) the formulation is stable for long-term storage at 50°C, 40°C, 25°C, 5°C, -20°C, -30°C, and -80°C; (ii) the formulation has low viscosity (viscosity less than 10 cP); (iv) the formulation is isotonic to physiological conditions; (v) the formulation is stable and compatible with intravenous or subcutaneous delivery devices and procedures; and (vi) the formulation is stable for long-term storage in a glass vial or prefilled syringe.

[0096] On the one hand, the preparation retains its physical and chemical stability and its biological activity substantially during storage. The shelf life is usually selected based on the expected shelf life of the preparation. A variety of analytical techniques for measuring protein stability are available in the art and are reviewed in, for example, Peptide and Protein Drug Delivery, 247-301, Vincent Lee, Marcel Dekker, Inc., New York, NY, published (1991) and Jones, A. Adv. Drug Delivery Rev., 10: 29-90 (1993). Stability can be measured at a selected temperature in a selected time period. For example, a liquid preparation is stable at about 40°C for at least about 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or 6 weeks. In another aspect, the liquid formulation is stable at about 5°C and / or 25°C for at least about 1 month, at least about 3 months, at least about 6 months, at least about 9 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 30 months, or at least about 36 months; and / or at about -20°C and / or -70°C for at least about 1 month, at least about 3 months, at least about 6 months, at least about 9 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 30 months, at least about 36 months, at least about 42 months, or at least about 48 months. In addition, in some embodiments, the liquid formulation can be stable after being frozen (to, e.g., -80°C) and thawed (e.g., after 1, 2, or 3 freeze and thaw cycles).

[0097] The stability of liquid formulations can be qualitatively and / or quantitatively assessed in a variety of different ways, including assessment of dimer, multimer and / or aggregate formation (e.g., using size exclusion chromatography (SEC), matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), analytical ultracentrifugation, light scattering (photon correlation spectroscopy, dynamic light scattering (DLS), static light scattering, multi-angle laser light scattering (MALLS)), flow-based microscopic imaging (flow-based microscopy), and / or quantitative analysis of the formation of dimers, multimers, and / or aggregates. imaging), electrical impedance (Coulter) counting, light obscuration or other liquid particle counting systems, by measuring turbidity and / or by visual inspection); assessing charge heterogeneity by using cation exchange chromatography (CEX), isoelectric focusing (IEF) (e.g., capillary technology (cIEF)), or capillary zone electrophoresis; amino-terminal or carboxyl-terminal sequence analysis; mass spectrometry analysis; SDS-PAGE or SEC analysis to compare fragmented, intact and multimeric (i.e., dimer, trimer, etc.) antibodies; peptide mapping (e.g., trypsin or LYS-C) analysis; evaluating the biological activity or antigen binding function of the antibody; and the like. The stability of the formulation in the solid state can also be qualitatively and / or quantitatively evaluated in a variety of different ways, including direct tests such as identification of crystal structure by X-ray powder diffraction (XRPD); evaluation of antibody structure in the solid state using Fourier transform infrared spectroscopy (FTIR); and measurement of thermal transitions (melting, glass transition, etc.) in lyophilized solids using differential scanning calorimetry (DSC) and indirect tests (such as measurement of moisture content by Karl Fisher test), for example, to infer the possibility of chemical instability caused by hydrolysis. Instability can involve any one or more of the following: aggregation (e.g., non-covalent soluble aggregation, covalent soluble aggregation (e.g., disulfide bond rearrangement / disorder), insoluble aggregation), deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), shearing / hydrolysis / fragmentation (e.g., hinge region fragmentation), succinimide formation, N-terminal extension, C-terminal processing, glycosylation differences, etc. Therapeutic use of pharmaceutical preparations

[0098] It should be understood that references to "treating" or "treatment" include prevention as well as alleviation of symptoms of an established condition. Thus, "treatment" of a state, disorder, or condition includes: (1) preventing or delaying the onset of clinical symptoms of a state, disorder, or condition that develops in a person who may have or is susceptible to the state, disorder, or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder, or condition, (2) inhibiting the state, disorder, or condition, i.e., arresting, reducing, or delaying the development of the disease or its recurrence (in the case of maintenance therapy) or at least one clinical or subclinical symptom thereof, or (3) remitting or attenuating the disease, i.e., causing regression of the state, disorder, or condition or at least one of its clinical or subclinical symptoms.

[0099] In one aspect, the disclosure provides a method of treating an inflammatory or autoimmune disease or condition in a patient in need thereof, the method comprising administering to the patient a liquid pharmaceutical formulation provided herein.

[0100] In certain embodiments, the inflammatory disease or condition is selected from the group consisting of Alzheimer's disease, Addison's disease, atherosclerosis, ankylosing spondylitis, arthritis, osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PA), ankylosing spondylitis, asthma, atherosclerosis, chronic obstructive pulmonary disease (COPD), Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematosus (SLE), nephritis, Parkinson's disease (PD), vasculitis, ulcerative colitis, and COVID-19.

[0101] In certain embodiments, the autoimmune disease or condition is selected from the group consisting of alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, diabetes mellitus (type 1), celiac disease, autoimmune juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, autoimmune myocarditis, multiple sclerosis, pemphigus / pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, scleroderma / systemic sclerosis, Sjögren's syndrome, systemic lupus erythematosus, autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune uveitis, vitiligo, and granulomatosis with polyangiitis (Wegener's granulomatosis).

[0102] "Subject" or "individual" or "animal" or "patient" or "mammal" means any subject, particularly a mammalian subject, for whom diagnosis, prognosis or therapy is desired. Mammalian subjects include humans, domestic animals, farm animals and zoo animals, competition animals or pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, etc.

[0103] As used herein, phrases such as "to a patient in need of treatment" or "a subject in need of treatment" include subjects, such as mammalian subjects, who would benefit from administration of an antibody or composition of the disclosure for, e.g., detection, diagnostic procedures, and / or therapy. Examples Example 1. Preparation of pH and buffer system

[0104] 155 ml of a purified anti-GM-CSF antibody (also referred to as "protein" in all experiments below, comprising heavy chain / light chain variable region sequences of SEQ ID NO: 14 and SEQ ID NO: 22, and having the Fc region of human IgG1) with a concentration of 24.20 mg / ml was taken and divided into 5 portions, namely, 3 portions of 17.22 ml and 2 portions of 49 ml; (2) each portion was dialyzed into buffer solutions 1 to 5 (see Table 4-1), and after the dialysis was completed, buffer solution 4 was divided into three portions, two of which were adjusted to pH 6.0 and pH 6.5 respectively with 10 mM histidine hydrochloride buffer (pH 8.14), and buffer solution 5 was divided into three portions, two of which were adjusted to pH 7.0 and pH 7.5 respectively with 20 mmol / L sodium dihydrogen phosphate solution (pH 9.44). Then, the 9 protein solutions were concentrated to a final protein concentration of 50 mg / ml, and the concentrated products were prepared into the following samples (see Table 4-2): Table 4-1 Recipe Number Solution formulation Preparation volume (L) 1 20mmol / L sodium acetate-acetic acid pH 4.5 1 2 20mmol / L sodium acetate-acetic acid pH 5.0 1 3 20mmol / L sodium acetate-acetic acid pH 5.5 1 4 10mmol / L Histidine HCl-Histidine pH 5.5 3 5 20mmol / L sodium dihydrogen phosphate-sodium hydrogen phosphate pH 6.5 3 Table 4-2

[0105] The samples were divided into packages (1 ml / tube), one tube of sample was used for detection at 0 h, and the other samples were placed at 40°C ± 2°C, and samples were taken for detection at 1, 2, and 4 weeks; DSC (0 h), appearance inspection, protein concentration detection, SEC purity determination, CE-SDS purity determination and CEX-HPLC were performed (see Tables 5-1 and 5-2 below). Table 5-DSC at 1.0h Sample batch number Tml(℃) Tm2(℃) 1 62.71718 87.84549 2 65.04998 86.6765 3 58.29477 84.0734 4 65.40558 87.88601 5 58.50304 83.045 6 59.48022 83.4227 7 61.27721 83.49064 8 61.61108 82.73536 9 61.58672 82.70817

[0106] From the DSC results, it can be seen that the Tm values ​​of samples in buffer solutions 1-9 are acceptable. By comparing the results of samples 1-9, the Tm values ​​are in the following relative decreasing order: 4>2>1>7>8=9>3>5>6. (> indicates excellent, = indicates equivalent). Table 5-Appearance inspection at 2.0h, 1 week, 2 weeks and 4 weeks

[0107] By comparing the remaining samples 1 to 6, the appearance results are in the following relative decreasing order: 4=2=1>5=3>6. (> indicates better than, = indicates equivalent), and all results are within the acceptable range (≤6NTU). Table 5-3.0h, 1 week, 2 weeks, 4 weeks protein concentration test results

[0108] No significant changes in protein concentrations among samples 1 to 6 were observed. Table 5-4. SEC purity determination at 0h, 1 week, 2 weeks and 4 weeks Note: “△Change” indicates the difference between the test result at 4 weeks and the test result at 0 hours.

[0109] According to the change of purity by SEC method, the reduction amplitude is in the following increasing order: 4=2<1<5<3<6 (the final value of sample 6 is less than 95%). Table 5 - CEX-HPLC results at 5.0 h, 1 week, 2 weeks and 4 weeks Note: “△Change” indicates the difference between the test result at 4 weeks and the test result at 0 hours.

[0110] According to the changes in the main peak of the CEX-HPLC method, the reduction amplitude was in the following increasing order: 6<3=4=5=2<1 (all changes in the results were within the acceptable range). Table 5-6. CE-SDS purity determination at 0h, 1 week, 2 weeks and 4 weeks Note: “△Change” indicates the difference between the test result at 4 weeks and the test result at 0 hours.

[0111] According to the change of purity determined by non-reducing CE-SDS, the reduction amplitude is in the following increasing order: 2 = 3 = 5 < 4 < 6 < 1

[0112] According to the change of purity determined by reducing CE-SDS, the reduction amplitude is in the following increasing order: 5<3=6<4<2<1 (the values ​​of samples 1 and 2 are less than 95%) Table 6. Summary of changes in stability results at 4 weeks Example 2. Screening of excipient composition Table 7-1. Solution preparation

[0113] Take 306.68 ml of purified protein with a concentration of 8.627 mg / ml. Dialyze the protein into buffer solution 1 in Table 7-1 and concentrate to 30 ml with a concentration of 84.34 mg / ml. Then add 10 ml of buffer solution 1 and divide it into 9 equal parts, each with 4.4 ml. Add 1.1 ml of buffer solutions 2, 3, 4, 5, 6, 7, 8, 9 and 10 in Table 7-1 to each part, respectively, to prepare the following samples in Table 7-2: Table 7-2 Sample batch number formula 1 pH 5.8 20mmol / L histidine hydrochloride, 130mmol / L sucrose 2 pH 5.8 20mmol / L histidine hydrochloride, 130mmol / L trehalose 3 pH 5.8 20mmol / L histidine hydrochloride, 130mmol / L mannitol 4 pH 5.8 20mmol / L histidine hydrochloride, 260mmol / L proline 5 pH 5.8 20mmol / L histidine hydrochloride, 150mmol / L arginine hydrochloride 6 pH 5.8 20mmol / L histidine hydrochloride, 260mmol / L glycine 7 pH 5.8 20mmol / L histidine hydrochloride, 150mmol / L sodium chloride 8 pH 5.8 20mmol / L histidine hydrochloride, 0.02% polysorbate 20 9 pH 5.8 20mmol / L histidine hydrochloride, 0.02% polysorbate 80

[0114] The stability of each sample was investigated based on the results of DSC (at 0 h), appearance inspection, protein concentration detection, SEC purity determination, and CE-SDS purity determination after being placed at 50°C for 1 week. Table 8-DSC results at 1.0h The Tm values ​​of plonmarlimab in excipient solutions 1-9 were acceptable. Table 8-Appearance inspection at 2.0h, 2 days, 4 days and 1 week

[0115] From the appearance observation results, it can be seen that the appearance of formula samples 1-9 after being placed at 50°C for 1 week is within the acceptable range, and the appearance results are in the following relative decreasing order: 1=2=3=4=6=8=9>5>7. Table 8-Concentration test results at 3.0h, 96h and 1 week

[0116] After being placed at 50°C for one week, no significant changes were observed in the protein concentrations of formulations 1-9. Table 8-SEC purity determination results at 4.0h and 1 week

[0117] After being placed at 50°C for one week, the purity of formulations 1-9 determined by SEC method was >97%, and the variation of the results was within an acceptable range. Table 8 - Results of CEX-HPLC at 5.0 h and 1 week

[0118] The purity of formulations 1-9 determined by CEX-HPLC at 0 h was very different, that is, the highest and lowest values ​​differed by 9%; in contrast, after being placed at 50°C for 1 week, the highest and lowest values ​​differed by 4.0%, which was within an acceptable range. Therefore, the results at 0 h were used as the basis for formulation selection. The results at 0 h followed the following ranking: 1 (51.9%) = 7 > 2 = 4 = 6 = 8 > 9 > 3 > 5 (42.9%). Table 8- CE-SDS purity determination results at 6.0h and 1 week

[0119] After the samples were placed at 50°C for one week, the change in purity according to the non-reducing CE-SDS method showed a decreasing order as follows: 1=3=4<2=7=8<5=6=9; the change in purity according to the reducing CE-SDS method showed a decreasing order as follows: 1=5=6=7=2=9=4<3=8. All results were within an acceptable range.

[0120] According to the changes in the stability results at 50°C for 1 week (see Table 9 below), the conditions of different surfactants were compared, and there was no significant difference between polysorbate 80 and polysorbate 20. The conditions of the remaining excipients were compared, excluding the CEX-HPLC results, and the results of samples 1 and 4 were similar, slightly better than the other formulations. Table 9. Summary of changes in stability results at 50°C for 1 week Note: The appearance changes are in a relatively decreasing order, and △ represents the difference in the result changes. Example 3. Study on protein solubility

[0121] The solubility and viscosity of the protein at concentrations of 100 mg / ml and 150 mg / ml in a histidine hydrochloride buffer system (pH 5.8) were studied to confirm whether the protein sample could be prepared into a high-concentration product for subcutaneous injection. 3.73 g of the original protein sample was dialyzed into 20 mmol / L histidine hydrochloride (pH 5.5), and then the pH was adjusted to 5.8 with 20 mmol / L histidine hydrochloride (pH 6.5). 84.44 ml, 126.65 ml and 80 ml of the solution were taken, respectively, and concentrated to prepare the following samples: Table 10-1.

[0122] Each batch is 2ml / tube, and there are 6 tubes for samples 1 and 2 respectively, of which 2 tubes are used for testing at 0h, 2 tubes are placed at 4℃ and sampled at 48h for testing, and 2 tubes are placed at 25℃ and sampled at 48h for testing. Sample 3 is divided into 5 tubes, placed at 25℃ and sampled at 48h for clarity testing. The test items include appearance / color, protein concentration, OD350, viscosity and clarity (see Table 10-2 and Table 10-3). Table 10-2. Test results Table 10-3. Results of the clarity test at 48h:

[0123] In a 20mmol / L histidine hydrochloride buffer system (pH 5.8), when the protein concentration was 100mg / ml and 150mg / ml and the sample was placed at 4°C and 25°C for 48h, the appearance color, clarity, OD350, protein concentration and viscosity did not change significantly, wherein the viscosity was less than 10cP and the clarity was less than 6NTU. Therefore, the protein disclosed herein can be developed into a high-concentration preparation for subcutaneous injection. Example 4. Verification of excipient concentration

[0124] The appropriate sucrose concentration was selected based on viscosity and osmotic pressure, the durability and stability at pH 5.8 (the working range of pH is 5.5-6.1) were investigated, and the concentration of polysorbate 80 in the formulation was measured. Table 11-1. Solution preparation

[0125] Take three portions of protein, 480 μl each, add 120 μl of solution A, B and C to each portion to prepare the following samples shown in Table 11-2, mix the samples well, and then measure the protein concentration and viscosity respectively: Table 11-2. Sample solution formula Table 12. Test results

[0126] As shown in Table 12, there is no difference in protein concentration among samples a, b, and c, the viscosity of the three samples is acceptable, and the viscosity decreases with decreasing sucrose concentration. Example 5. Experimental study on osmotic pressure Table 13-1. Solution preparation

[0127] Take 6 portions of protein, 480 μl each, and add 120 μl of solutions D, E, F, G, H and I to each portion to prepare the following samples in Table 13-2: Table 13-2. Formula of sample preparations

[0128] After mixing evenly, the protein concentration and osmotic pressure were tested respectively, and the D to I formula solutions were diluted 5X with 20 mmol / L histidine hydrochloride buffer solution (pH 5.8), and then the osmotic pressure was tested. The test results are shown in Table 14 below. Table 14. Osmotic pressure test results Example 6. Verification of pH and Tween content Table 15-1. Solution preparation

[0129] 3.6g of protein was dialyzed into 20mmol / L histidine hydrochloride buffer solution (pH 5.5), divided into three parts with volumes of 30.47ml, 103.45ml and 30.41ml, respectively, the pH was tested and adjusted to 5.5, 5.8 and 6.1, respectively, and then concentrated to a final concentration of 125mg / ml using an ultrafiltration centrifuge tube, and the concentrated volumes were 9.04ml, 33.26ml and 7.95ml, respectively. 9.6ml of pH 5.8 protein solution was taken out, and the other two protein solutions were used to add 1 / 4 volume of buffer solutions 1, 2 and 3 to the three protein solutions, respectively, to prepare samples 1 to 3 (see Table 15-2) for studying the effects of different pH.

[0130] The remaining 23.26 ml of protein solution (pH 5.8) in step (1) was divided into three equal parts, each containing 7.45 ml. 1.86 ml of buffer solutions 4, 2 and 5 were added to each part, respectively, to prepare samples 4 to 6 (see Table 15-2) for studying the effects of different concentrations of polysorbate 80. Table 15-2. Formula of sample preparations Sample No. Preparation formula 1 pH 5.5 20 mM histidine hydrochloride, 200 mmol / L sucrose, 0.02% polysorbate 80 2 pH 5.8 20mM histidine hydrochloride, 200mmol / L sucrose, 0.02% polysorbate 80 3 pH 6.1 20 mM histidine hydrochloride, 200 mmol / L sucrose, 0.02% polysorbate 80 4 pH 5.5 20mM histidine hydrochloride, 200mmol / L sucrose 5 pH 5.5 20 mM histidine hydrochloride, 200 mmol / L sucrose, 0.02% polysorbate 80 6 pH 5.5 20 mM histidine hydrochloride, 200 mmol / L sucrose, 0.04% polysorbate 80

[0131] Aliquot: 2 ml / tube for each batch. For samples 1 to 3, one tube was used for testing at 0 h, and the other samples were placed at 40°C and sampled for testing at 1 week, 2 weeks, and 4 weeks; for samples 4 to 6, 2 tubes were used for testing at 0 h, and the other samples were placed at 50°C and sampled for testing at 1 week. The test items included appearance (Table 16-1), protein concentration (Table 16-2), SEC purity (Table 16-3), CE-SDS purity (Table 16-4), and CEX-HPLC purity (Table 16-5). Table 16-1. Results of clarity test Table 16-2. Protein concentration test results Table 16-3. SEC results Table 16-4. Results of CEX-HPLC Table 16-5. CE-SDS results

[0132] By comparing the stability at 40°C for 4 weeks, it was found that the pH value fluctuated in the range of 5.5 to 6.1, the appearance and protein concentration did not change significantly, and the purity changes by SEC, CEX-HPLC and CE-SDS methods were all within an acceptable range.

[0133] Based on the stability comparison at 50°C for 1 week, it was found that when the concentration of polysorbate 80 was in the range of 0-0.04%, except for a slight abnormality in the CEX-HPLC results (the purity at a polysorbate 80 concentration of 0.04% decreased faster than that at low polysorbate concentrations), the other results of appearance, protein concentration, SEC purity, and CE-SDS purity at different polysorbate 80 contents did not differ much. Example 7. Adjustment of formulation buffer solution

[0134] Considering the convenience and controllability of commercial production, the present disclosure adjusts the ratio of histidine to histidine hydrochloride to achieve the purpose of directly obtaining the target pH. In addition, the content of sucrose (osmotic pressure regulator) is also adjusted. Table 17. Preparation of buffer solutions

[0135] The pH of formulations 1 to 6 and the osmotic pressure of formulations 3 and 4 were tested. Table 18-1. pH test results Table 18-2. Osmotic pressure test results

[0136] The osmotic pressure of Formulation 4 is closer to the osmotic pressure of the buffer solutions in Table 18-2. Example 8. Adjustment of the recipe

[0137] Through 50L process development, the pH value and osmotic pressure measurement of batch stock solution were carried out. It was found that for large-scale production, the pH value was higher than the theoretical value and the osmotic pressure value was lower than the theoretical value. Therefore, the formulation of the preparation was adjusted. 8.1 Adjustment of pH and buffer concentration Table 19. Solution formulation

[0138] The original protein sample was taken and divided into 5 equal parts, and dialyzed into the above buffer solution with 10 times the volume. The sample batch numbers were Yu-1, Yu-2, Yu-3, Yu-4 and Yu-5, and the protein concentration and pH value of the samples were tested. The dialyzed samples were concentrated to 100 mg / ml using ultrafiltration centrifuge tubes with batch numbers 1, 2, 3, 4 and 5, and the protein concentration and pH value of the samples were tested. Table 20. Protein concentration and pH of samples Sample batch number Protein concentration (mg / ml) pH Yu-l 17.32 6.05 Yu-2 13.33 5.88 Yu-3 11.73 5.80 Yu-4 10.70 5.68 Yu-5 9.20 5.59 1 103.33 6.04 2 101.37 5.88 3 101.73 5.79 4 103.92 5.68 5 100.45 5.57 8.2 pH Verification

[0139] The effect of fluid exchange using concentrators and ultrafiltration systems on pH and osmolality was confirmed by comparing small-scale formulation development with the 50-L process. Table 21-1. Solution preparations and corresponding pH, osmotic pressure and conductivity

[0140] Take 150.21 ml of the protein stock solution and divide it into three parts, number them a, b and c, dialyze them into buffer solutions 1 to 3 respectively, and then use ultrafiltration centrifuge tubes to concentrate to 100 mg / ml. Take another part of the protein stock solution and number it d. Use two 0.005m 2 The protein was dialyzed into buffer solution 2 using a membrane package (Sartocon Slice Cassette Hydrosart, 30 kD, Sartorius) and concentrated to 100 mg / ml. The test items included protein concentration, osmotic pressure, pH and conductivity (see Table 21-2).

[0141] The buffer concentration and sucrose concentration of Formulation 2 were the same as those of the confirmed batch used for process development. The osmotic pressure of the sample was higher than that of the confirmed batch sample when concentrated to 100 mg / ml using an ultrafiltration centrifuge tube. In contrast, the osmotic pressure of the sample was similar to that of the confirmed batch sample and was lower than 300 mOsmol / kg when concentrated to 100 mg / mL using a membrane package. In other words, the concentration method used in the preparation process of the protein sample disclosed herein has an effect on the osmotic pressure of the concentrated sample. Therefore, in subsequent experiments, the sucrose concentration was adjusted and 0.005 m 2 The membrane samples were prepared to study the osmotic pressure. Table 21-2. Test results of samples

[0142] In addition, from the pH test results, it was found that the method used to concentrate the samples had no effect on the pH, and the pH of samples ad were all in the range of pH 5.5-pH 6.1. Example 9. Verification of sucrose concentration

[0143] A buffer solution containing 6.2 mmol / L histidine and 13.8 mmol / L histidine hydrochloride was used. By comparing different sucrose concentrations, the sucrose concentration in the formula when the osmotic pressure was 300 mOsmol / kg was confirmed, the formulation formula was confirmed, the stock solution was prepared, and the density of the dialysis buffer solution disclosed herein and the density of the protein stock solution were tested. Table 22. Solution formulation

[0144] The protein solution was dialyzed into buffer solution 1 and concentrated to 100 mg / ml to obtain a stock solution of batch number protein stock solution 1, which was tested for protein concentration, osmotic pressure and pH. 8.99 g of the protein solution was dialyzed into buffer solution 2 to prepare a stock solution of batch number protein stock solution 2, which was tested for protein concentration, osmotic pressure and pH; in addition, its concentration and the concentration of the corresponding dialysis buffer solution were measured. The results are shown in Tables 23-1 and 23-2 below. Table 23-1. Test results of protein concentration, pH and osmotic pressure Table 23-2. Density test results of buffer solution and protein sample

Claims

1. A liquid pharmaceutical formulation comprising: (a) 20 mg / ml-200 mg / ml of an antibody or antigen-binding fragment thereof that specifically binds to human granulocyte macrophage colony-stimulating factor (GM-CSF) protein, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region CDR1 (HCDR1) of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2, HCDR3 of SEQ ID NO: 3, a light chain variable region CDR1 (LCDR1) of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5, and LCDR3 of SEQ ID NO: 6; (b) 10 mM-30 mM pH buffer; (c) 130 mM to 250 mM isotonicity regulator; and (d) 0.01% (w / v) - 0.03% (w / v) surfactant, Wherein the formulation has a pH of 4.5 to 7.

5.

2. The liquid pharmaceutical formulation of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising one or more amino acid residues selected from the group consisting of: (a) Glu at position 1, (b) Arg at position 98, (c) Ser at position 72, (d) Ala at position 68, (e) Leu at position 70, (f) Ile at position 48, (g) Asp at position 26, and (h) Leu at position 29, and combinations thereof.

3. The liquid pharmaceutical formulation of claim 2, wherein the heavy chain variable region comprises at least (a) Glu at position 1.

4. The liquid pharmaceutical formulation of claim 2, wherein the heavy chain variable region comprises a DYTLT (SEQ ID NO: 23) or GYTFT (SEQ ID NO: 24) fragment starting at position 26 according to Kabat numbering.

5. The liquid pharmaceutical formulation of any one of claims 1 to 4, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising one or more amino acid residues selected from the group consisting of: (a) Ala at position 46, (b) Asp at position 60, (c) Asp at position 70, (d) Ser at position 43, and (e) Phe at position 87, and combinations thereof.

6. The liquid drug formulation of any one of claims 1 to 5, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-17.

7. The liquid drug formulation of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19-22.

8. The liquid drug formulation of any one of claims 1 to 7, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

22.

9. The liquid pharmaceutical formulation of any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof further comprises an Fc region.

10. The liquid drug formulation of claim 9, wherein the Fc region is the Fc region of IgG1.

11. The liquid pharmaceutical formulation of any one of claims 1 to 10, wherein the pH buffer comprises citric acid, HEPES, PBS, histidine, potassium acetate, potassium citrate, potassium phosphate (KH2PO4), sodium acetate, sodium bicarbonate, sodium citrate, sodium phosphate (NaH2PO4), Tris base and Tris-HCl.

12. The liquid pharmaceutical formulation of claim 11, wherein the pH buffer comprises about 20 mM histidine.

13. The liquid pharmaceutical formulation of claim 12, wherein the 20 mM histidine comprises about 6.2 mM histidine and about 13.8 mM histidine hydrochloride monohydrate.

14. The liquid pharmaceutical formulation of claim 13, wherein the pH buffer comprises about 20 mM NaAc.

15. The liquid pharmaceutical formulation of any one of claims 1 to 14, wherein the pH ranges from about 5.5 to about 6.

1.

16. The liquid pharmaceutical formulation of claim 15, wherein the pH is about 5.

8.

17. The liquid pharmaceutical formulation of any one of claims 1 to 16, wherein the isotonicity adjusting agent is one or more selected from the group consisting of sucrose, trehalose, mannitol, arginine and sodium chloride.

18. The liquid pharmaceutical formulation of claim 17, wherein the isotonicity adjusting agent comprises about 200 mM to about 220 mM sucrose.

19. The liquid pharmaceutical formulation of claim 18, wherein the isotonicity adjusting agent comprises about 220 mM sucrose.

20. The liquid pharmaceutical formulation of any one of claims 1 to 19, wherein the liquid pharmaceutical formulation further comprises an antioxidant, a preservative, or a mixture thereof.

21. The liquid drug formulation of any one of claims 1 to 19, wherein the liquid drug formulation further comprises proline and / or glycine.

22. The liquid pharmaceutical formulation of any one of claims 1 to 21, wherein the surfactant comprises polysorbate 20 or polysorbate 80.

23. The liquid pharmaceutical formulation of claim 22, wherein the surfactant comprises 0.02% (w / v) polysorbate 80.

24. The liquid drug formulation of any one of claims 1 to 23, wherein the liquid drug formulation comprises 50-150 mg / ml of the antibody.

25. The liquid drug formulation of claim 24, wherein the liquid drug formulation comprises 100 mg / ml of the antibody.

26. The liquid drug formulation of any one of claims 1 to 25, wherein the liquid drug formulation comprises 50-150 mg / ml of the antibody, 10-20 mM histidine, 200-220 mM sucrose, and 0.01-0.03% (w / v) polysorbate 80, and has a pH of about 5.5 to about 6.

1.

27. The liquid drug formulation of claim 26, wherein the liquid drug formulation comprises about 100 mg / ml of the antibody, about 20 mM histidine, about 220 mM sucrose, and about 0.02% (w / v) polysorbate 80, and has a pH of about 5.

8.

28. The liquid pharmaceutical formulation of any one of claims 1 to 27, which is for intravenous (IV) or subcutaneous administration.

29. A method of treating an inflammatory or autoimmune disease or condition in a patient in need thereof, the method comprising administering to the patient the liquid pharmaceutical formulation of any one of claims 1 to 28.

30. The method of claim 29, wherein the autoimmune disease is selected from the group consisting of alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, diabetes mellitus (type 1), celiac disease, autoimmune juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, autoimmune myocarditis, multiple sclerosis, pemphigus / pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, scleroderma / systemic sclerosis, Sjögren's syndrome, systemic lupus erythematosus, autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune uveitis, vitiligo, and granulomatosis with polyangiitis (Wegener's granulomatosis).

31. The method of claim 29, wherein the inflammatory disease is selected from the group consisting of Alzheimer's disease, Addison's disease, atherosclerosis, ankylosing spondylitis, arthritis, osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PA), ankylosing spondylitis, asthma, atherosclerosis, chronic obstructive pulmonary disease (COPD), Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematosus (SLE), nephritis, Parkinson's disease (PD), vasculitis, ulcerative colitis, and COVID-19.

Citation Information

Patent Citations

  • GM-CSF antibody and application thereof

    CN107840885A

  • Anti-GM-CSF antibodies and uses thereof

    CN109219616A

  • Treatment for giant cell arteritis

    CN113453759A

Cited By

  • Application of neutralizing antibody of GM-CSF in preparation of medicine for improving radiation resistance

    CN120661650A